Ekaterina Krasimirova Kurteva

Dr. Ekaterina Krasimirova Kurteva

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2019 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
GVGeorgi Hristov Vasilev
Georgi Hristov Vasilev
MIMariana Ivanova
Mariana Ivanova
EIEkaterina Ivanova-Todorova
Ekaterina Ivanova-Todorova
KTKalina Tumangelova-Yuzeir
Kalina Tumangelova-Yuzeir
EKEkaterina Krasimirova Kurteva
Ekaterina Krasimirova Kurteva
DKDobroslav Kyurkchiev
Dobroslav Kyurkchiev

20 January 2022 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
EKEkaterina Krasimirova Kurteva
Ekaterina Krasimirova Kurteva
GVGeorgi Hristov Vasilev
Georgi Hristov Vasilev
KTKalina Tumangelova-Yuzeir
Kalina Tumangelova-Yuzeir
Irena Dimitrova IvanovaIrena Dimitrova Ivanova
Irena Dimitrova Ivanova
EIEkaterina Ivanova-Todorova
Ekaterina Ivanova-Todorova
DKDobroslav Kyurkchiev
Dobroslav Kyurkchiev

29 March 2022 in Life
Verified
Journal Article
Open access
PDF file
Sevdalina LambovaSevdalina Lambova
Sevdalina Lambova
EKEkaterina Krasimirova Kurteva
Ekaterina Krasimirova Kurteva
SDSanie Dzhambazova
Sanie Dzhambazova
GVGeorgi Hristov Vasilev
Georgi Hristov Vasilev
DKDobroslav Kyurkchiev
Dobroslav Kyurkchiev
MGMariela Gencheva Geneva-Popova
Mariela Gencheva Geneva-Popova
Introduction: Data on the associations between capillaroscopic changes and diagnostic systemic-sclerosis (SSc)-related antibodies are scarce. Presence of such correlation would improve current knowledge about the disease’s pathogenesis by revealing the mechanisms of microangiopathy. The microvascular pathology of SSc is a hallmark of the disease, and immunological abnormalities probably contribute to its development. Patients and methods: 19 patients with definite diagnosis of SSc were included in the current pilot study; 16 had limited and 3 had diffuse cutaneous involvement; their mean age was 51.56 ± 15.07 years. All patients exhibited symptoms of Raynaud’s phenomenon of the fingers. A “scleroderma” type capillaroscopic pattern was classified according to the staging suggested by Cutolo et al. (2000): “early”, “active” or ”late” phase. In the presence of different degrees of capillaroscopic changes in different fingers, the most-advanced microvascular pathology was chosen for classification. In cases without capillaroscopic features of microangiopathy, the findings were categorized as normal or nonspecific (dilated, tortuous capillaries, and/or hemorrhages). Indirect immunofluorescence on HEp-2 cells was performed as the gold-standard screening method for the detection of antinuclear autoantibodies (ANA), and determination of the immunofluorescent staining pattern (anti-cell pattern) was in accordance with the International Consensus on ANA Patterns. Scleroderma-associated autoantibodies in the patients’ serum were assessed using line immunoblot assay for detection of autoantibodies to 13 scleroderma-associated autoantigens: Scl-70, CENP A, CENP B, RP11/RNAP-III, RP155/RNAP-III, fibrillarin, NOR-90, Th/To, PM-Scl100, PM-Scl75, Ku, PDGFR, and Ro-52. Results: In 73.7% (n = 14) of the examined patients, “scleroderma” type capillaroscopic changes were found, and in 26.3% (n = 5), capillaroscopic features of microangiopathy were absent (nonspecific changes, n = 3; normal findings, n = 2). In SSc patients with positive anti-Scl-70 (n = 7) antibodies, significantly lower mean capillary density was observed along with a higher frequency of “active” and “late” phase capillaroscopic changes as compared to the anti-Scl-70-negative patients (p < 0.05). Anti-RNAP III–155 positive patients (n = 4) had significantly higher mean capillary density than anti-RNAP III–155 negative patients (n = 15). In three of the anti-RNAP III–155-positive cases, capillaroscopic features of microangiopathy were not detected, and in one case there was an “early” phase “scleroderma” pattern. Conclusion: In the current pilot study, the association between more advanced capillaroscopic changes and the presence of anti-Scl-70 autoantibodies was confirmed. As a novel observation, positive anti-RNAP III–155 antibodies were found in SSc patients with or without early microangiopathy. The question of associations between microvascular changes in SSc and other SSc-related autoantibodies requires further research.

1 May 2023 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
BPBogdan Frediev Penev
Bogdan Frediev Penev
GVGeorgi Hristov Vasilev
Georgi Hristov Vasilev
EIEkaterina Ivanova-Todorova
Ekaterina Ivanova-Todorova
KTKalina Tumangelova-Yuzeir
Kalina Tumangelova-Yuzeir
EKEkaterina Krasimirova Kurteva
Ekaterina Krasimirova Kurteva
DKDobroslav Kyurkchiev
Dobroslav Kyurkchiev

22 January 2020 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
EKEkaterina Krasimirova Kurteva
Ekaterina Krasimirova Kurteva
VBVladimira Boyadzhieva
Vladimira Boyadzhieva
NSNikolay Rumenov Stoilov
Nikolay Rumenov Stoilov

Verified
Journal Article
Open access
PDF file
KTKalina Tumangelova-Yuzeir
Kalina Tumangelova-Yuzeir
KMKrasimir Minkin
Krasimir Minkin
IAIvan Angelov
Ivan Angelov
EIEkaterina Ivanova-Todorova
Ekaterina Ivanova-Todorova
EKEkaterina Krasimirova Kurteva
Ekaterina Krasimirova Kurteva
DKDobroslav Kyurkchiev
Dobroslav Kyurkchiev
The central hypothesis for the development of glioblastoma multiforme (GBM) postulates that the tumor begins its development by transforming neural stem cells into cancer stem cells (CSC). Recently, it has become clear that another kind of stem cell, the mesenchymal stem cell (MSC), plays a role in the tumor stroma. Mesenchymal stem cells, along with their typical markers, can express neural markers and are capable of neural transdifferentiation. From this perspective, it is hypothesized that MSCs can give rise to CSC. In addition, MSCs suppress the immune cells through direct contact and secretory factors. Photodynamic therapy aims to selectively accumulate a photosensitizer in neoplastic cells, forming reactive oxygen species (ROS) upon irradiation, initiating death pathways. In our experiments, MSCs from 15 glioblastomas (GB-MSC) were isolated and cultured. The cells were treated with 5-ALA and irradiated. Flow cytometry and ELISA were used to detect the marker expression and soluble-factor secretion. The MSCs’ neural markers, Nestin, Sox2, and glial fibrillary acid protein (GFAP), were down-regulated, but the expression levels of the mesenchymal markers CD73, CD90, and CD105 were retained. The GB-MSCs also reduced their expression of PD-L1 and increased their secretion of PGE2. Our results give us grounds to speculate that the photodynamic impact on GB-MSCs reduces their capacity for neural transdifferentiation.